293 related articles for article (PubMed ID: 33830879)
21. Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm.
Hu S; Gu S; Wang S; Qi C; Shi C; Qian F; Fan G
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741835
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
23. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
24. A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
Wang W; Zhang X; Jiang S; Xu P; Chen K; Li K; Wang F; Le X; Zhang K
Front Immunol; 2023; 14():1187286. PubMed ID: 37691944
[TBL] [Abstract][Full Text] [Related]
25. DTL Is a Prognostic Biomarker and Promotes Bladder Cancer Progression through Regulating the AKT/mTOR axis.
Luo Y; He Z; Liu W; Zhou F; Liu T; Wang G
Oxid Med Cell Longev; 2022; 2022():3369858. PubMed ID: 35103094
[TBL] [Abstract][Full Text] [Related]
26. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
[TBL] [Abstract][Full Text] [Related]
27. Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
Shen C; Bi Y; Chai W; Zhang Z; Yang S; Liu Y; Wu Z; Peng F; Fan Z; Hu H
BMC Med Genomics; 2023 Oct; 16(1):264. PubMed ID: 37880682
[TBL] [Abstract][Full Text] [Related]
28. The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients.
Jiang L; Chen S; Pan Q; Zheng J; He J; Sun J; Han Y; Yang J; Zhang N; Fu G; Gao F
BMC Cancer; 2022 Jun; 22(1):676. PubMed ID: 35725413
[TBL] [Abstract][Full Text] [Related]
29. Impact of tumour stroma-immune interactions on survival prognosis and response to neoadjuvant chemotherapy in bladder cancer.
Liu L; Xu L; Wu D; Zhu Y; Li X; Xu C; Chen K; Lin Y; Lao J; Cai P; Li X; Luo Y; Li X; Huang J; Lin T; Zhong W
EBioMedicine; 2024 Jun; 104():105152. PubMed ID: 38728838
[TBL] [Abstract][Full Text] [Related]
30. Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer.
Luo Y; Chen L; Zhou Q; Xiong Y; Wang G; Liu X; Xiao Y; Ju L; Wang X
J Cell Mol Med; 2020 Nov; 24(22):13370-13382. PubMed ID: 33048468
[TBL] [Abstract][Full Text] [Related]
31. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
32. Ubiquitination-Related Molecular Subtypes and a Novel Prognostic Index for Bladder Cancer Patients.
Cai H; Chen H; Huang Q; Zhu JM; Ke ZB; Lin YZ; Zheng QS; Wei Y; Xu N; Xue XY
Pathol Oncol Res; 2021; 27():1609941. PubMed ID: 34776794
[No Abstract] [Full Text] [Related]
33. KRT13-expressing epithelial cell population predicts better response to chemotherapy and immunotherapy in bladder cancer: Comprehensive evidences based on BCa database.
Yu D; Chen C; Sun L; Wu S; Tang X; Mei L; Lei C; Wang D; Wang X; Cheng L; Li S
Comput Biol Med; 2023 May; 158():106795. PubMed ID: 36989746
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of machine learning-based pathomics signature for diagnosis and survival prediction of bladder cancer.
Chen S; Jiang L; Zheng X; Shao J; Wang T; Zhang E; Gao F; Wang X; Zheng J
Cancer Sci; 2021 Jul; 112(7):2905-2914. PubMed ID: 33931925
[TBL] [Abstract][Full Text] [Related]
35. Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti-PD-L1 Immune Checkpoint Therapy.
You S; Kim M; Hoi XP; Lee YC; Wang L; Spetzler D; Abraham J; Magee D; Jain P; Galsky MD; Chan KS; Theodorescu D
J Natl Cancer Inst; 2022 Oct; 114(10):1380-1391. PubMed ID: 35918812
[TBL] [Abstract][Full Text] [Related]
36. Machine learning identifies the role of SMAD6 in the prognosis and drug susceptibility in bladder cancer.
Chen Z; Ou Y; Ye F; Li W; Jiang H; Liu S
J Cancer Res Clin Oncol; 2024 May; 150(5):264. PubMed ID: 38767747
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis.
Chen S; Huang M; Zhang L; Huang Q; Wang Y; Liang Y
Comput Struct Biotechnol J; 2024 Dec; 23():369-383. PubMed ID: 38226313
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of cadherin-11 for subsequent recurrence and progression in non-muscle invasive bladder cancer.
Chen MK; Chen ZJ; Xiao KH; Qin ZK; Ye YL; Wen WJ; Bian J; Xue KY; Zhou QZ; Guo WB; Zhou JH; Xia M; Li X; Liu CD
Jpn J Clin Oncol; 2020 Apr; 50(4):456-464. PubMed ID: 31894237
[TBL] [Abstract][Full Text] [Related]
39.
Goswami S; Chen Y; Anandhan S; Szabo PM; Basu S; Blando JM; Liu W; Zhang J; Natarajan SM; Xiong L; Guan B; Yadav SS; Saci A; Allison JP; Galsky MD; Sharma P
Sci Transl Med; 2020 Jun; 12(548):. PubMed ID: 32554706
[TBL] [Abstract][Full Text] [Related]
40. Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
Lee YH; Lee MM; De Silva DM; Roy A; Wright CE; Wong TK; Costello R; Olaku O; Grubb RL; Agarwal PK; Apolo AB; Bottaro DP
PLoS One; 2021; 16(7):e0241766. PubMed ID: 34292953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
